This weight gain was associated with reversal of improvements in blood pressure, cholesterol, blood glucose and insulin sensitivity, reinforcing the need for continued treatment in adults living with obesity. Details from phase III of Novo Nordisks EVOKE trial, announced on 24 November 2025, found that glucagon-like peptide-1 receptor semaglutide had no effect on the progression of cognitive decline in people with Alzheimers disease, despite previous hopes that it could slow the disease
Hypothalamic mTOR signaling regulates food intake
A 2019 Aging study demonstrated methylated B vitamin supplementation for 8 weeks reduced GrimAge epigenetic clock scores in subjects with elevated homocysteine one of the few direct human interventions with measured epigenetic age impact
Nausea is the most common side effect, affecting approximately 24-30% of patients across clinical trials, typically beginning during the early weeks of treatment
If you are struggling with obesity or struggling to manage your blood sugar but cannot access brand-name tirzepatide due to high prices or availability issues, compounded tirzepatide may be a good alternative